While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...
Novo Nordisk and Eli Lilly have used submissions to the federal government’s budget process to argue reducing obesity will be ...
Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...
Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on ...
Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead this lucrative and fast-growing market. However, Novo Nordisk (NYSE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback